• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn’s buprenorphine depot wins priority review from FDA

September 18, 2017 By Sarah Faulkner

Camurus, Braeburn PharmaceuticalsBraeburn Pharmaceuticals said today that the FDA granted priority review to the company’s CAM2038 NDA. The investigational weekly and monthly buprenorphine depot injection was designed to treat adults with opioid use disorder.

The regulatory agency is slated to make a decision about CAM2038 by January 10, 2018.

“FDA’s acceptance of our NDA for CAM2038 under priority review represents an important step in advancing Braeburn’s mission to provide opioid use disorder patients with effective treatment options which can be individualized to support them throughout their recovery – from initiation and stabilization, to longer-term maintenance,” president & CEO Mike Derkacz said in prepared remarks.  “Because the weekly and monthly formulations are administered by healthcare professionals and remain in their control, if approved, CAM2038 may help mitigate the inherent risks of daily oral medication in terms of diversion, misuse and pediatric exposure.”

The subcutaneous injection is set to be offered in dosage strengths for once-weekly and once-monthly administration in prefilled syringes.

CAM2038’s NDA included positive results from a pivotal Phase III trial, demonstrating non-inferiority versus treatment with the current standard of care – a daily sublingual buprenorphine/naloxone product.

Braeburn’s depot also had a safety profile that was consistent with the known safety profile of buprenorphine, except for some mild-to-moderate adverse events at the injection site.

Researchers have evaluated CAM2038 in seven clinical trials, as well as a long-term safety study, Braeburn reported.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS